High-Affinity CD19 for CAR-T Cell Therapy
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus | NEJM
JCI - HIV-specific CAR T cells return to the clinic
Professor John G Gribben explains why CART-cell therapy has the potential to revolutionise cancer treatment. | Middle East Medical Portal
Frontiers | Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | Biomarker Research | Full Text
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis - The Lancet Haematology
Frankel – Chimeric Antigen Receptor T Cells-Charting the Course from Clinical Trials to Commercialization
Frontiers | Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Is Anti-CD19 CAR T Cell therapy helpful in refractory SLE? The Visual Abract — NephJC
CD19-CAR-T Cells | Encyclopedia MDPI
In Vitro Characterization of CD19 CAR T Cells Derived by Electroporation of mRNA | MaxCyte
EHA 2018: competition is heating up in DLBCL for anti-CD19 CAR-T cell therapies - Pharmaceutical Technology
Evaluating CD19 CAR expression levels in clinical trial and quality checks
CASI Pharmaceuticals | CNCT19
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges - ScienceDirect
Efficacy and safety of humanized CD19 CAR‑T as a salvage therapy for recurrent CNSL of B‑ALL following murine CD19 CAR‑T cell therapy
Cells | Free Full-Text | Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant | Leukemia
Tisagenlecleucel (Kymriah) Drug Information
CAR-T Cell Therapy - WuXi Biology
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies - ScienceDirect
Chimeric antigen receptor car t cell therapy | solution for detection | Miltenyi | Miltenyi Biotec | Deutschland
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer: Molecular Therapy
